-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CMXbai9nE82yx45481R0o2qYTwbn4Pa8NPretTP1KPosbwGe9XrZsHj0j8NFAMNJ
 p5ul2qaE10aNDTEZqjrLzw==

<SEC-DOCUMENT>0001119774-04-000027.txt : 20040902
<SEC-HEADER>0001119774-04-000027.hdr.sgml : 20040902
<ACCEPTANCE-DATETIME>20040902112720
ACCESSION NUMBER:		0001119774-04-000027
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20040902
FILED AS OF DATE:		20040902
DATE AS OF CHANGE:		20040902

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		041012803

	BUSINESS ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		STREET 2:		TEL AVIV
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
		BUSINESS PHONE:		011-972-3-765-8585
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>sept1st2004.htm
<DESCRIPTION>SEPTEMBER 1, 2004 6K
<TEXT>
<html>
<head>
<meta name=Generator content="Microsoft Word 10 (filtered)">
<title>Sept 1st 2004</title>

<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman";}
h1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman";}
h2
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman";
	color:black;}
h3
	{margin-top:0in;
	margin-right:28.35pt;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman";}
h4
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:150%;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	text-decoration:underline;}
h5
	{margin-right:0in;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman";}
h6
	{margin:0in;
	margin-bottom:.0001pt;
	line-height:150%;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman";}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
a:link, span.MsoHyperlink
	{color:#000066;
	background:white;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
span.tdfont1
	{font-family:Verdana;
	color:#484848;
	font-weight:normal;}
span.msoIns
	{text-decoration:underline;
	color:teal;}
@page Section1
	{size:8.5in 11.0in;
	margin:1.0in 1.25in 1.0in 1.25in;}
div.Section1
	{page:Section1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
- -->

</head>
<body lang=EN-US link="#000066" vlink=purple>
<div class=Section1>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b><i
style='font-size:11.0pt'>&nbsp;</i></b></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>FORM 6-K</b></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b><i
style='font-size:11.0pt'>&nbsp;</i></b></p>
<h3 Style="margin-top:0in;

	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman""> Washington, D.C. 20549</h3>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b><i
style='font-size:11.0pt'>&nbsp;</i></b></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>Report of Foreign Private Issuer</b></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b><i
style='font-size:11.0pt'>&nbsp;</i></b></p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Pursuant to rule 13a-16 or 15d-16 of the Securities
Exchange Act of 1934</p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">for the month of September 2004</p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><u style='font-size:11.0pt'>Compugen Ltd.</u></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">(Translation of registrant's name in English)</p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><u style='font-size:11.0pt'>72 Pinchas Rosen Street, Tel-Aviv 69512, Israel</u></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">(Address of principal executive offices)</p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p  Style="text-align:justify;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F.</p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Form 20-F&nbsp;&nbsp;<u> X&nbsp;&nbsp;</u>             Form
40-F&nbsp;___</p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</i></p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p  Style="text-align:justify;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">On September 1st, 2004 Compugen Ltd. (the
&quot;Registrant&quot;) issued a Press Release, filed as Exhibit 1 to this
Report on Form 6-K, which is hereby incorporated by reference herein.</p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b>&nbsp;</b></p>
<p align=center  Style="text-align:center;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b><u style='font-size:11.0pt'>SIGNATURE</u></b></p>
<p  Style="margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p  Style="text-align:justify;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.</p>
<p  Style="margin-left:28.35pt;margin-right:28.35pt;margin-top:0in;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin-left:4.0in; margin-bottom:.0001pt;margin-right:28.35pt;margin-top:0in;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">                                    </p>
<p  Style="text-indent:225.0pt;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Compugen Ltd.</p>
<p  Style="text-indent:225.0pt;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">(Registrant)</p>
<p  Style="text-indent:225.0pt;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">By:    <u>/s/ Mor Amitai</u></p>
<p  Style="text-indent:225.0pt;margin-right:28.35pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Title:  President &amp; CEO</p>
<p  Style="text-indent:225.0pt;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Date: September
1st, 2004</p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:11.0pt'>&nbsp;</i></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b style='font-size:11.0pt'>Exhibit 1</b></p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman""><img width=257 height=136
src="image001.jpg"></p>
<p align=center  Style="text-align:center;font-weight:bold;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">Compugen Appoints Vice President, Biology Research </p>
<p align=center  Style="text-align:center;font-weight:bold;margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">and Development</p>
<p align=center  Style="text-align:center;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><i
style='font-size:14.0pt'>&nbsp;</i></p>
<p  Style="text-autospace:none;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b>TEL AVIV, ISRAEL, September
1st, 2004</b> - Compugen Ltd. (Nasdaq: CGEN)
announced today the appointment of Noam Shani, Ph.D., as Vice President of
Biology Research and Development. <!-- Created Using Viltech Software --></p>
<p  Style="text-autospace:none;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p  Style="text-autospace:none;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">In
this position, Dr. Shani will lead Compugen`s drug research and development
activities, with direct management responsibility for therapeutic protein
candidate discovery, selection, validation, and preclinical and clinical
development. In addition, as a member of the Company`s senior management team,
he will be a key participant in further developing and implementing Compugen`s
strategy and corporate development activities. Dr. Shani will report to Mor
Amitai, Ph.D., President and Chief Executive Officer.<!-- Created Using Viltech Software --></p>
<p  Style="text-autospace:none;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p  Style="text-autospace:none;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">"Dr. Shani
is joining our senior management team during a period of significant progress
and advancement for our Company," stated Dr. Amitai.&nbsp;&nbsp;"I am confident
that his experience, talent, and energy will very quickly make him a key factor
in achieving rapid and efficient advancement of promising therapeutic and
diagnostic candidates from discovery research and selection into clinical
development."<!-- Created Using Viltech Software --></p>
<p  Style="text-autospace:none;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p  Style="text-autospace:none;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">"I am
delighted to join Compugen at this exciting time in the Company`s evolution. I
have been impressed with Compugen`s team and their unique approach to drug and
diagnostic discovery that stems from the integration of advanced mathematics
and computational technologies with biology.&nbsp;&nbsp;I look forward to
becoming a part of this team and contributing to the Company`s continuing
growth and future success," commented Dr. Shani. <!-- Created Using Viltech Software --></p>
<p  Style="text-autospace:none;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p  Style="text-autospace:none;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">Dr.
Shani joins Compugen from Medgenics Inc., where he served as Vice President of
Research and Development and led the development of the company`s technologies
and applications, including all biological and clinical research. Prior to
Medgenics, Dr. Shani was a senior scientist and project manager at
Biotechnology General Ltd. In this capacity, he headed the company`s generic
recombinant protein drug development activities. Dr. Shani holds a doctoral
degree in biology from the Weizmann Institute of Science, Israel, and completed
a postdoctoral fellowship at Johns Hopkins University`s School of Medicine,
Maryland. <!-- Created Using Viltech Software --></p>
<p  Style="text-autospace:none;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p  Style="text-autospace:none;margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;<!-- Created Using Viltech Software --></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b>&nbsp;</b></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman""><b style='font-size:8.0pt'>About Compugen </b></p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:8.0pt;font-family:"Times New Roman"">Compugen, a genomics-based
drug and diagnostic discovery company, increases the probability of successful
development of novel drug and diagnostic products by incorporating ideas and
methods from mathematics, computer science, and physics into biology, chemistry
and medicine. This unique capability results in powerful predictive models and
discovery engines, which are both advancing the understanding of important
biological phenomena and enabling the discovery of numerous potential
therapeutic products and diagnostic markers. The Company has an early stage
in-house pipeline consisting of selected therapeutic protein candidates
discovered by the Company; additional discoveries have been out-licensed for
development. Among Compugen`s customers and partners are leading pharmaceutical
and diagnostic companies, such as Abbott Laboratories, Diagnostic Products
Corporation, Novartis, and Pfizer. Compugen has established a small-molecule
drug discovery subsidiary - Keddem Bioscience, and an agricultural
biotechnology subsidiary - Evogene. For additional information, please visit Compugen's
corporate Website at www.cgen.com.<!-- Created Using Viltech Software -->
</p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman"">&nbsp;</p>
<p Style="margin:0in;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman"">This press release contains
&quot;forward-looking statements&quot; within
the meaning of the Private Securities Litigation Reform Act of 1995.&nbsp;&nbsp;<!-- Created Using Viltech Software -->These
<!-- Created Using Viltech Software -->statements include words like &quot;may,&quot; &quot;expects,&quot;
&quot;believes,&quot; and &quot;intends,&quot; and describe opinions about
future events. These forward-looking statements involve known and unknown risks
and uncertainties that may cause the actual results, performance or
achievements of Compugen to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking
statements. Some of these risks are: changes in relationships with
collaborators; the impact of competitive products and technological changes;
risks relating to the development of new products; the ability to implement
technological improvements; the ability of Compugen to obtain and retain
customers. These and other factors are identified and more fully explained
under the heading &quot;Risk Factors&quot; in Compugen's annual reports filed
on form 20F that are filed with the Securities and Exchange Commission.</p>
<P Style="font-size:10.0pt;font-family:"Times New Roman"" align=center><B>1 </B>&nbsp;</P></div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image001.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 image001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#__@`<4V]F='=A<F4Z($UI8W)O<V]F="!/
M9F9I8V7_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-#AT5%A$8(Q\E)"(?(B$F
M*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_VP!#`0H+"PX-#AP0$!P[
M*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SO_P``1"`"(`0$#`2(``A$!`Q$!_\0`'``!``,!`0$!`0``````
M``````4&!P0#"`$"_\0`21```00!`@(%!0P%"@<``````0`"`P0%!A$2(0<3
M,4%1%")A<8$5%C)65Y&2E*'1TN$C,U*3TQ<E0E-B9G*DL<%4@J*RPN+P_\0`
M&0$!`0$!`0$```````````````$"`P0%_\0`+!$!``(!`@0$!04!````````
M``$"$0,$$B$QT4%1H?`3%&&QP3)QD;+A\O_=``0`*/_:``P#`0`"$0,1`#\`
MV9$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1
M$!$1`7X2&@DG8#F2O":[6@)9)9@CD`^"^0!5N6?4CY7.CU)@HV$^:SJ2>$>&
M_'S6ZUR.J?7.$@F?$77'EAV+HZ<KFGU$-YK^/?\`8/\`9O\`U"7\*Y>MU/\`
M&C!?5S^->5F]J&G7?8L:KP+(HQNYWDY.P]CUUBE/<_XCO]_V#_9O_4)?PK^9
M.D##L;O'7R<SB0`QE"3<_.`%4;NLK%RJZ#W\T:X=VR08V5KP/0>>RMFB\->J
M5SD+VH+>5%A@,'6%[6-8>>_"X]I]*U;3I2,VCW_`LL$AF@9*Z)\1>T'@?MQ-
M]!V[UZ(B\JB(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("X,M?MT*[9
M*>,FR$CG;=7$]K=AXDN*[U7=4P5XFLOW-09'%0-`C/DKO,))/,^:>?<M4C-L
M"%LUVW+#[-KHV?--(=WR22PN<X^LE>7N=5^3`?3A^]>/NCI_Y0<Q](_PT]T=
M/_*#F/I'^&O9BWE_9'J<?4:"3T8M`':3)`/]U"6:&9=9D=4T)@XX.+]&V01N
M<!Z2'C<KMR%K3-K'SPSZVR]R-S#O7+_UG?P\V=ZIVVC?^#S_`-.+[EUTXGWG
M\RBU8O$YFSE:L-W1^"BK/E`E>V-A+6]^VSSS6K-:&M#6@``;`#N6$8Z]I/%Y
M*O?K4\]UU>02,XG1;$CN/+L6RX+/4=0XYMVB\[=CXW#9T;O`A>?<UMRGP]_6
M5A)HB+R*_]#9D1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0%^$;]J_4
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M<2T/`Y@;@'O7>JCT>5IZ^,M=?@6X7BFY0@O/'YH\[SB?5[%;E\[4B*VF(:$1
M%@$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`7G-/%7B=+/*R*-HW<][@T
M#UDJ-RMS.PRAF*Q,%IO]*2:T(Q[``2HN>SJVS'U=C3.+E9OOPR7>(?,6+<4S
MS_,#VR6J,+;INAI:LH4I7$?IA(QY`]`)V4+[HL^4^O\`NH%V]3J'XFX3ZR/P
M*-FSLE>9T,^&TM'(P[.8[(,!:?`^8O16L=(_"/7W19\I]?\`=0+ARFI8<7$U
MYZ0I;;G'81U*<,CO6>X?.HZ]D<W:L%]:[I.E'W1QRPN^<N!W7E7&JK<[8*N5
MT[/,[X,<?D[G'V!B[12.LX].R(G(9+`Y2X^W=U'FY)G[;N%9C1R[.0?L%UX'
M3V+U)<\EQN7SCR.;Y75VAD8])X_L5TP.EM1OE$N>NT8XFG]17IPES_6[@Y#U
M*Z05H*S"RO#'$TG<B-H:"?8LWW$5C%??HN'/B,7!AL7!CZY<YD+=N)YW<X]Y
M/I)7:B+PS.9S*B(B@(B("(B`B(@(B("(B#__T=F1$0$1$!$1`1$0$1$!4C/9
M3"9.YP7(-0@UR6`58IF,)WYGS>WUJ[JHVI,W%;E8=9XJ#9YVBDK,XF#N!W?X
M+KI=??807#I?^HU7_F?O3ATO_4:K_P`S]ZF/*,U\>L/]69^-/*,U\>L/]69^
M->C/U]9[(K.4EQD,<?N5AM37G.)#Q+8LQ!H^W=07DM/Y/\E]9F_`K!JM\H=7
MGR6O&C?=C!CX#MX^<&/^TJ-PE&/.Y2*A2UOE)97[N+>IE;YHYGF7\EWI.*Y[
MHZ]-:4HY^X63:0LX^M'^LFGNR@^IK2T;E:3A-.8G3T!BQM-D/%\)YYO=ZW'F
M5W5J\=.K'7C+N")H:"]Q<=AXD]JRK5G2E>DNRT\"]L%>,EILEH<Z0]Y;OR`^
MU>;.IKVQ7HO1K:+"<AF=<85M2S?RER$6V=9"'2`[CEVM[NT<BK_HS71R>FKM
M[,O8U^-VZV5@V#VD<CMX]VWJ6;[:U:\43DRNZ+%,OTE:BS-T08ISJ44C^&**
M%H=(_<[#<GO]2X9]4:TP&2=7N9.W'8CV+HIR'C8C<<N86XVEYZS&3+>45'BU
MQ+>Z-KF<:&P786F$\(W`EY`$;_X@50:6OM7S7H(F9":RYTC0(6Q,WDY_!Y-[
MUBFVO;/T,MV18)E-;:M?DI>OR-BG+&\M->/S!&1W;?>I#(Z_U;8P--_GU(7;
ML==C9L;#AX'NV'AZ5OY2_+G!EM:+*.C75N:O:B]S+]R2Y!+$YP,O-S".>^_A
MW*)S_2#J%FH+[*.4=%59.YD3!&P@-!V[QZ%GY6_'-<F6VHL-R6KM;G%4[-BS
M8JU901%.Q@89CXDC\AR5HZ,]99+)W+&,RM@V0R$S1S/'G``@$$]_:EMM:M>+
M)EI2+"+G2+J=]R=\&5?'"9'&-@B9YK=^0[/!6G6.J<YA,#@88<@YE^Q!UMF3
M@:2[D.6VVPYD_,D[6\3$9ZF6G(LNT#JW,7K.1NYO)ODH4*O6/!8T#<GEV`=P
M*KN:Z1M0Y>Z[R*U)1KEVT4,')VW=N>TE(VMYM-?(RW-%AUW6.M\,R/'7K4U:
M=OZ0.EC:9'-/8"2#N.1]*M.@M5Y*QCLME\_D72TZ36@;L:.?,G;8#<]@]JEM
MM:M>+,&6D(L7N](&J-2Y5M+#%U1LS^&&&$#C/^)Q]'AL%QV-3ZTTQEW5KV2F
M,\6Q=%,X2L<"-Q_\%J-I?IF,^1ENB+/M5ZVM1Z&QF4QLIJV<@\=@#N$`'B',
M>(V52P^NM9V;Q97FER+Q&XB$0M([/A'8`[#M6:[:]J\1EMR+Y^&N]4LM>4^[
M-@N!WX#MP>KAVVV6[XVR^[BZEN1H8^>%DCFCN)`*SJZ%M+&2)=2(BX**MZ@Q
MD/E+;$&D:F8EFWZV1[HV.:1MMOQ#G^2LB\;=<6ZLM=TDD0D:6\<3^%[?2#W%
M:K;AG(I?D$GR9TOW\'W)Y!)\F=+]_!]REO>8WXPY[Z]^2>\QOQASWU[\EW^)
M7S^_=$%>QN0DIR,Q_1[0JV2!P2O?`]K>?>W;FO?05?)LR-M^2HXBN6QAK#1;
M%Q[[\P>`D[<AVJ6]YK?C#GOKWY+TP&C<;IR_9O4YK4DUINTKIY`[BY[[]@Y[
MJSJ5X)COW'3JN:6OI3*2P;]8VJ_;;M')?/\`BX8I\K3AG>UD+YV->YQV`:7#
M??V+Z5DC9+&Z.1H>QX+7-(W!![0L]R'0]C9[#I*.1GJ1N._5.8)`WT`[@[+6
MVUJ4B8L3#^=6:\T]7RWD,N$@S`KM`$W$PM:3VM&X/H49JB[!=Z-H[V/PS,5#
M<NM#V1@?I&M#MG'8#EN/L4SC.B'$5)FR7KD]UK3N(MA&P^O;F?G5SO8BAD<6
M_&6:S'5',#.K`V#0.S;;LV[DG4TJ37AYX&&Z#DI0ZQI3Y">."&+B?QR.V:'!
MIVY^M<^L,M'FM4WK\+N*%S^&)WBUHV!]NV_M5]L=#5-TI-;,3QQD\FR1->1[
M=PI7!]%V$Q-AEFR^7(31G=O7`!@/CPCM]NZ]$[C2BW'GGA,2I&5K38/HPH4I
MVF.;)VS9<P\B&`<M_P#I*\NC"HV?5S;4@_1TH'S.)[N7"/\`5:5JO1%?5EBO
M+9O3UQ786M9&&D'<\SS]07A@^CZG@:N1AKW[#WWX>I,CFMWC'/LV'I^Q<OF*
M_#F/&5PQ7(VW7\C:N/YNGE?(?:25;]>_S=@=-X,<C#5ZZ0?VG;?[\2LL70[B
MXY6/.4MN#7`\):S8[=W8I34G1W4U+ECD+&1LPGJVQMCC:WA:!ZQZ5TG<:<VK
MSY0F%)Z,FBD,WG'CS:5,AI/B=S_X_:J*29'%SSS<=R?6M6U'@ZNA^CR_3JV)
M)G9"=C"^0`'GMRY=VS3\ZH.DL/'GM34\=,'&&0DR\)V/"`2>:ZZ=XGBU/#L+
M#TB9W&W*.(Q.)LQV(:<7$]T9W:#PAK1Z]M_G7+HR*6CA-0Y[A(9!3->-WB]^
MW9ZN7SJT,Z&J0L<3\Q8=!O\``$30[;PXOR5S][6+;IU^!CK]72?&6%K3SY_T
MM_'?GNO/;7TZTBE>9A\]TF0ONUV6'B.$RM$CSV-;N-S\RL72%FZN;U,9*,PE
MJUX6PQO;V';<G;VG[%<(.ANBRR'3Y>Q+`#OU;8PUQ'AQ?DNBUT08FQ:DEBOV
M:['NW;$QK>%@\!N%UG<:4VBV3$J?3KRU.B?(6V`CRV]'&XC]AO\`[*$TM8HU
M-3X^SD9!'5AF#WN()`V&XY#T[+4,_/BM#:2IX2UCY<G2L<<;B7!I)WXMSZ>?
M+;P5"QS]!S6WNNP9:M$UO$UAF$@<?V?-;O\`:KIWXJVG$XD<^N,[#J'4\]RJ
MXNK-:V*(D;;@=^WI)*E+5>6AT0U"T$"_?ZR0^(`(;_V@JK]2[+9DPXZKPFS,
M1!`S^B">0]@[UO?O9H3Z6AP%R/K:\<+(R0=CQ`?"![COS4UKUTHI!#$-,85F
M<R,E=^5BQG5Q%XED.V_,#8<QW%=$N)T]U[F.U6^5X=P\3:$CN(]G([\U=)>A
MBJZ0]5FIFQ[\FO@:XCV[C_13FGNC3"X*TRY(Z6]9C.['3;!K#XAH[_7NI;<T
MZQ;T,,_U_$,7#A,`R4R-HU"]SBWAW<\^'=V+KZ/_`.;=.ZCSAY&*OU,9_M$$
M_P"O"KEJ'HVIZBS,V3L9.S&^4-'`QK=F@#;EN%[PZ`IP:2GT['>L-BL3=;)-
MPMXSS'+LVVY!<YUZ?#BN?W_)AB5"JZ]?K5&\W3RMC'M("^EHHVPQ,B8-FL:&
MM'@`J3A^BS'8C+ULBW(69G5G\;6/:W8GN[`KRN6YU:ZDQPK$"(B\BB(B#__2
MV9$1`1$0$1$!$1`1$0$1$!$1!&YG`8W4$$<&3KF>.-W&UO&YNQVVWY%<N)T;
M@<'=\LQU'J9^$LX^L<[D>WM*G$6HO:(QGD"(BR"(B#DR6,HY>FZID*T=B!QW
M+'CO\1X%5EW17I5S^(5K#1^R+#ME<46ZZEZ_ID1&&TMA<`2[&T(X9"-C*=W/
M(_Q'FI=$69F9G,@B(H"(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(
5B`B(@(B("(B`B(@(B("(B`B(@__9
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
